Taysha Gene Therapies Inc (TSHA) 2023 Q1 法說會逐字稿

Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene Therapies First Quarter 2023 Earnings Conference Call. (Operator Instructions) And the conference is being recorded. (Operator Instructions) I would now like to turn the conference over to Hayleigh Collins, Director, Head of Corporate Communications. Please go ahead.

Thank you. Good afternoon, and welcome to Taysha's First Quarter 2023 Financial Results and Corporate Update Conference Call. Earlier today, Taysha issued a press release announcing financial results for the first quarter 2023. A copy of this press release is available on the company's website and through our SEC filings.

Joining me on today's call are Sean Nolan, Pasha's CEO; Sukumar Nagendran, President and Head of Research and Development; Kamran Alam, Chief Financial Officer; and Salman Bhai, Assistant Professor of Neurology at UT Southwestern. We will hold a question-and-answer session following our prepared remarks.

Please note that on today's call, we will be making forward-looking statements, including statements relating to the existing clinical data TSHA-120, the therapeutic and commercial potential of TSHA-120 and TSHA-102. These statements may include the expected timing and results of clinical trials for our product candidates in other clinical and regulatory plans and the market opportunity for those programs. This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway and future operating results, discovery, and development of product candidates, strategic alliances, and intellectual property as well as matters that are not historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements.

These risks include uncertainties related to the timing and results of clinical trials of and regulatory interactions for our product candidates, our dependence upon strategic alliances and other third-party relationships; our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties, and the requirements of substantial funding to conduct our research and development activities. For a list and description of these risks and uncertainties that we face, please see the reports we have filed with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2022.

The conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 11, 2023. Taysha undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities laws. With that, I would now like to turn the call over to our CEO, Sean Nolan.

Thank you, Hayleigh, and welcome, everyone, to our 2023 first-quarter financial results and corporate update conference call. Today, I will begin with a brief corporate update. Then Dr. Suku Nagendran, President and Head of R&D of Taysha, will provide an update on our clinical development programs, along with our collaborator, Dr. Salman Bhai, Assistant Professor of Neurology at UT Southwestern. Kamran Alam, our Chief Financial Officer, will then follow up with a financial update before I provide closing remarks and open the call up for questions.

We've made significant progress across 2 lead programs in Rett syndrome and giant axonal neuropathy this year and remain on track to deliver on multiple key milestones, including the generation of first-in-human clinical data for TSHA-102 in adult patients with Rett syndrome, the submission of a CTA to the MHRA to initiate expansion of TSHA-102 in pediatric patients, the submission of an IND application to the FDA for TSHA-102, and obtaining further clarity from the FDA on the regulatory path forward for TSHA-120 in GAN.

Screening is completed and the dosing of our first potential patient with TSHA-102 in the Phase I/II REVEAL trial in adult Rett syndrome is scheduled for the second quarter of this year. For our GAN program, the new comprehensive analyses of the totality of the data for TSHA-120 continues to be encouraging and includes compelling findings that offer potential to further support a regulatory path forward. I want to highlight that much of the data presentation planned for the FDA will be new to the agency, and we will work to contextualize the data in a manner that clearly elucidates the potential for meaningful benefit to patients. We plan to submit the meeting request this quarter and expect the formal meeting to occur in the third quarter of this year.

In the near term, we look forward to hosting an R&D Day in June, where we will provide an overview of the GAN disease state and share these new clinical data analyses. Additionally, we plan to provide an update on our Rett program. Suku and Salman will discuss this in more detail shortly. At the upcoming ASGTC conference, new preclinical data supporting TSHA-102 and the miRARE technology in Rett syndrome will be presented as part of a poster presentation. We remain focused on achieving the anticipated near-term milestones for our Rett syndrome and GAN programs and continue to work towards our mission of bringing transformation on new treatments to patients with these devastating neurodegenerative diseases. I will now turn the call over to Suku to provide a more in-depth discussion of our clinical programs in Rett syndrome and GAN. Suku?

Thank you, Sean, and good afternoon, everyone. First, I will start with an update on TSHA-102, our gene therapy program in development for the treatment of Rett syndrome. As a reminder, TSHA-102 utilizes an innovative miRNA-responsive auto-regulatory element or miRNA platform to regulate the cellular expression of MECP2. At the upcoming ASGCT conference, we are excited to present new preclinical data that we believe supports the potential for TSHA-102 and the miRNA technology as part of a poster presentation on May 19.

For our Phase I/II REVEAL study in adult patients with Rett syndrome, we have completed screening and scheduled the dosing for the first potential patient. We expect the dosing to take place in the second quarter of 2023. We plan to report initial available clinical data, which will be primarily on safety in the second quarter of the year at our upcoming R&D Day. In the second half of the year, we plan to continue dosing adult patients with Rett syndrome in our REVEAL trial and provide quarterly updates on available clinical data thereafter.

We received feedback from Health Canada on our protocol amendment to expand enrollment eligibility to subject 15 years or older in the REVEAL trial, which suggests that Health Canada supports the expansion following initial efficacy and safety data from adult patients. We plan to submit a CTA to the U.K. MHRA for TSHA-102 in mid-2023 to enable the initiation of a pediatric Rett syndrome study.

We also have an IND application submission to the U.S. FDA plan in the second half of the year to further expand our clinical study footprint with TSHA-102. Now let's turn to TSHA-120 for the treatment of GAN, an ultra-rare neurodegenerative indication with no approved treatments or established regulatory pathway.

As Sean mentioned, we are currently completing a comprehensive review of data from the ongoing natural history and interventional trial that includes functional biological and electrophysiological assessments. We plan to seek a formal meeting with the FDA to discuss a new analysis that FDA has not seen and the regulatory path forward for TSHA-120. As a reminder, early analysis based on MFM32, the primary efficacy scale discussed at the FDA Type B end of Phase II meeting, demonstrated a clinically meaningful slowing of disease progress in patients with GAN following treatment with TSHA-120 across the therapeutic dose cohorts. Importantly, long-term analysis points to sustained durability and the ability of TSHA-120 to prevent nerve degeneration, generate nerve fibers, and preserve visual equity, which are significant findings for patients affected by neurodegeneration.

Importantly, over 6 point years of long-term clinical safety data supports a well-tolerated safety profile with no major drug-delayed events. The FDA has stated that MFM32 can be a relevant primary endpoint in the setting of a randomized, double-blind controlled trial and acknowledge Taysha's challenge in executing and enrolling such a study design due to the ultra-rare nature of GAN. As such, the FDA indicated that it is open to regulatory flexibility in a controlled trial setting and is willing to consider alternative study designs utilizing objective measurements to demonstrate a relatively large treatment effect that is self-evident and clinically meaningful.

Our comprehensive analysis of the totality of data from the ongoing natural history and interventional trial, which will inform our plans for future interactions with the FDA, continues to be encouraging and includes compelling new findings with the potential to further support our regulatory path forward. I will now turn the call over to our collaborator, Dr. Salman Bhai from UT Southwestern, who will provide a high-level overview of some of our initial analysis of the data for TSHA-120 in GAN and the clinical relevance to the disease state. Salman?

Thank you, Suku, and hello, everyone. My name is Dr. Salman Bhai, and I'm an Assistant Professor of Neurology at UT Southwestern. I earned my medical degree and completed my neurology clinical training at Harvard Medical School with a subspecialization and neuromuscular disorders. As a practicing neuromuscular neurologist, I'm keenly aware of the devastation that GAN causes not only to patients but also to their families. I've been working closely with Taysha on the development of the TSHA-120 program for over 1.5 years and am energized by the opportunity to help bring a potentially transformational treatment to the GAN community.

I've been heavily involved in the ongoing comprehensive analyses of the totality of data and have been working collaboratively with the team to identify new data findings. Based on the GAN clinical phenotype and pathophysiology, we are building a clinical narrative around the data to support our regulatory path forward for TSHA-120. I'm pleased to provide an update on the compelling findings from our ongoing data analysis. One goal of evaluating the totality of the data for TSHA-120 is to determine whether we can identify potential objective measurements that demonstrate a clinically meaningful treatment effect. For context, I think it's important to understand that GAN clinically manifests with marked incortination, ataxia, due to both severe central and peripheral nervous system degeneration.

We leached the significant disability and early mortality caused by respiratory failure. There is no approved treatment for this ultra-rare fatal disease. We have access to the largest natural history database of GAN to date through the NIH. As a result of our analysis of these data, we have a clear understanding of how to measure meaningful treatment effects for these patients. I'm a neurologist. So of course, let's start with the neuroanatomy. We know their central and peripheral nervous system degeneration with GAN. Specifically, this involves the cerebellum, long track, and sensory-motor nerves.

Clinically, these anatomical localizations translate to severe incoordination, which is ataxia and weakness. Patients struggle with simple tasks like picking up objects and feeding themselves. How can we measure this, the integration of the central nervous system and the peripheral nervous system pathologies? We believe we have a comprehensive scale that we prospectively collected in the natural history and interventional patients, the modified Frederic ataxia rating scale, or mFARS, which was recently used as the primary outcome measure for drug approval for Frederic's ataxia.

This scale is based on functional and objective measures within the neurologic exam focusing on ataxia, a key driver of disability in GAN patients. As a whole, we can prospectively measure the integration of the central and peripheral nervous systems using mFARS. We can then capture several objective peripheral nervous system data points, including nerve conduction studies, myometry, and nerve pathology. We have scientific evidence of TSHA-120 leading to peripheral nerve regeneration in some patients, meaning nerves are growing back.

Nerve conduction studies indicate sensory nerves recover responses that were absent prior to treatment, a key finding that was truly unexpected and to my knowledge has never been demonstrated previously in GAN patients. We also see an increase in regenerative clusters on nerve biopsy. This is direct electrophysiologic and biological evidence of nerve regeneration. In neurodegenerative disease, the peripheral nervous system data is key because recovery of sensory nerves directly impacts patients' performance on mFARS, providing links between objective biologic data and a clinical rating scale.

Importantly, by developing a disease progression model through basin analysis based on the natural history data, we show that the progression of mFARS in GAN is predictable, monotonic, and homogenous across patients. Thus, we can use this model to determine the treatment effect. Preliminary determinations of treatment effect size relative to the disease progression model, as measured by mFARS and with multiple peripheral nervous system endpoints show disease slowing. Let me repeat. We have a direct central nervous system and peripheral nervous system outcome measures in clinical and biological objective data that show positive disease modification with TSHA-120 in an ultrarare, fatal, neurodegenerative disorder that has no approved treatment.

The restoration of sensory nerve responses on nerve conduction studies and positive impact on other clinically relevant endpoints show the potential for even greater clinical impact in this neurodegenerative disorder if treated at an earlier stage of disease with TSHA-120. I believe these data have the potential to provide objective measurements that demonstrate clinically meaningful treatment effects. We are truly, truly inspired by these patients and their caregivers. We are hopeful that we can bring a potentially transformational treatment to the GAN community, and we look forward to working collaboratively with the FDA through our anticipated future discussions. With that, I'll now turn the call back to Suku.

Thank you, Salman. As you can see, we have compelling findings that we expect to submit as a part of our formal meeting request to the FDA in the second quarter of this year. These data will inform our discussions with the FDA regarding alternative study designs, additional objective measures, and ultimately, a regulatory path forward. We anticipate a formal meeting to occur in the third quarter of 2023. Importantly, the administration of TSHA-120 also shows a translational correlation between preclinical and clinical studies. With TSHA-120, GAN (inaudible) show improved oral root canal pathology and motor function, both of which translate to our human studies with improved sensory integrity and sensory nerve action potential, better known as SNAP, as detected by nerve conduction studies and biopsy analysis and improvement of stabilization in strength.

We saw similar clinical translational impact with spinal muscular atrophy and the SMN delta 7 mouse model, which we developed Zolgensma at AveXis, which showed improvement of stabilization in motor function and strength after treatment with gene therapy that for congruous we seen in human studies as well. In June, we are excited to host a virtual R&D Day where we will detail this new analysis and review therapeutic potential in the context of the GAN disease state as well as provide an update on our red syndrome program, including new preclinical data for TSHA-102 in Rett syndrome being presented at the upcoming ASGCT Annual Meeting and available clinical data from Phase I/II REVEAL trial in adults.

Lastly, with respect to manufacturing, we have completed the CMC module 3 amendment submission detailing our commercial process product manufacturing and drug comparability analysis and are awaiting feedback from the FDA. We continue to believe in the transformative potential of TSHA-120 and look forward to having a collaborative dialogue with the FDA regarding the potential registrational path to bring TSHA-120 to patients with GAN who to reiterate, have no approved treatments. I will now turn the call over to Kamran to discuss financials. Kamran?

Thank you, Suku. Research and development expenses were $12.5 million for the 3 months ended March 31, 2023, compared to $38.2 million for the 3 months ended March 31, 2022. The $25.7 million decrease was due to reduced research and development compensation as a result of a lower head count of $10.7 million. The decrease was also due to reduced manufacturing and other raw material purchases of $7.1 million. We also incurred $6.4 million reduced expense in nonclinical studies related to translational and toxicology studies and $1.5 million lower expense in other research and development activities.

General and administrative expenses were $8.8 million for the 3 months ended March 31, 2023, compared to $11.5 million for the 3 months ended March 31, 2022. The decrease of $2.7 million was due to reduced general and administrative compensation as a result of a lower head count and reduced consulting and professional fees.

Net loss for the 3 months ended March 31, 2023, was $17.6 million or $0.28 per share as compared to a net loss of $50.3 million or $1.32 per share for the 3 months ended March 31, 2022. The net loss for the 3 months ended March 31, 2023, was partially offset by revenue of $4.7 million recognized related to the Astellas transaction. As of March 31, 2023, Taysha had $63.4 million in cash and cash equivalents. Taysha continues to expect that its current cash resources will support planned operating expenses and capital requirements into the first quarter of 2024. I will now turn the call back over to Sean for his closing remarks. Sean?

Thank you, Kamran. We believe that the clinical and preclinical data generated to date across our Rett syndrome and GAN programs reinforce our gene therapy approach and the therapeutic potential for our innovative programs to address severe unmet needs in monogenic central nervous system disease. In the year ahead, we are focused on executing across our near-term milestones in our rep syndrome and GAN programs. In the second quarter of this year, we look forward to dosing the first potential adult patient with Rett syndrome and reporting initial clinical safety data for TSHA-102.

We are excited to host an R&D Day in June to review the analysis of the totality of the data for TSHA-120 that will inform our regulatory path forward for TSHA-120 as well as provide an update on our Rett syndrome program. We look forward to providing further updates on our programs throughout the year. With that, I will now ask the operator to begin Q&A. Operator?

(Operator Instructions) The first question comes from Yanan Zhu with Wells Fargo Securities.

This is [Juan Hang] for Yanan. Congratulations on the progress. So first, on the GAN program. So I wonder -- thanks for the color on the new analysis. I wonder if the patient data would be compared to their own control, like pretreatment progression, or be compared to the natural history. And I wonder if there is a clear bar on what levels of change on those readouts, clinically meaningful.

Yes. So I will answer the question based on how I understood it. And if I do not, please clarify your question. So the analysis that is still ongoing, we do plan to compare each patient to their own pretreatment status as well based on the natural history that has been collected by the NIH. But we also have the option of looking at the broader data set in the national list database, where there were 52 patients with a mix of all types of GAN, which include Tessin and nonclassic GAN. And I would remind you that in these 2 types, again, the root cause of the disease is the same. Hence, the gene therapy and its findings, I think, will lead to hopefully a very productive discussion with the FDA if and when we get that meeting. I hope that answers the core of your question. Was there a second part to your question that I may have missed?

Yes. The second part is, for those readouts, is there a clear bar on what levels of clinical meaningfulness?

Great question. It's important to understand clinically what's not only important for the patients, but also for the families, right? A simple number on miRNAs that changes doesn't necessarily mean it's important to the patient. And that's why we work closely with patients and have interviews with families, too, to identify what's most important from them. As a clinician, it's important for me to understand that patients enjoy independence. And we're looking at our data to correlate objective biologic data with functional clinical outcome measures to define how that link is there and what it means for patients.

When we have that data in totality, we are seeing positive trends. But of course, this is preliminary. We also use data from other diseases that have ataxia and peripheral nervous system disease to come up with correlates. As you know, this is an ultra-rare disease. So to clearly identify clinical meaningfulness for this disease alone is difficult and perhaps impossible. However, if we correlate it to other diseases and other clinical syndromes related to this, we can come up with very good proxies that would give you a reasonable answer for what patients think is important.

The next question comes from Jack Allen with Baird.

This is [Avi Gray] on for Jack Allen. Recently, we've seen the FDA leadership make what appears to be a significant push to pursue the accelerated approval pathways for gene therapies, I guess, namely Starpeta's product in DMD. And we release that you're still discussing the regulatory pathway for GAN, but we're hoping you could provide some color surrounding the correlations you're seeing between functional endpoints, such as the MFM32 score, and the more objective biomarker endpoints, such as the rental vein thickness and your biopsy results.

Excellent question. right. When we take a look at functional clinical measures, of course, there's an issue with sometimes there's bits or effort dependence, and that's where we turn to biology. And that's in the biology, that's where the question of accelerated approval can come in. So specifically, if we're looking at sensory nerve action potential, for example, something that we're seeing recover that was not previously there. Well, that feeds into the feedback into your coordination for mFARS. In motor function as well, if you have deafferentation of your muscles, meaning you can't feel where your muscles are, your strength will decrease. And so having these kinds of markers correlate to clinical measures is important.

We take it a step further because sensorineuraction potentials are electrophysiology. We had nerve biopsies that show axonal regeneration preliminarily. As we evaluate this data, we can also look for giant axons decreasing. And that gets closer and closer to the biology. So we can then tie and correlate that biology from histology to clinical data to functional outcome measures and have a very clear trajectory of what's happening to the patient. Does that answer your question?

Can I add a little bit also a little bit of more information which I think is relevant? As Dr. Salman walked you through, to spin step back and look at GAN, albeit an ultra-rare disease. There's no therapeutic option available. Obviously, you need an intervention where the benefit outweighs the risk. And in our assessment using the predefined efficacy endpoints per the protocol in the interventional study, looking at the model that we've generated, looking at the progression of the disease, looking at post-hoc analysis, what we're seeing collectively at this point in time is a trend when it comes to functional, physiological biological electrophysiological and potentially the ideologic impact of the intrathecal gene therapy that affects the broad spectrum of the disease in the central nervous system and the peripheral nervous system in a clinically meaningful way. So hopefully, once you complete the analysis and we go to the FDA and receive that meeting, we can make our case for an appropriate regulatory path, which may hopefully result in approval sooner rather than later.

The next question comes from Kristen Kluska with Cantor Fitzgerald.

This is Rick on for Kristen. Just to ask about maybe you could add a little bit more color on the preclinical Rett syndrome data guided for ASGCT this month. How could we kind of put this into context as it relates to other preclinical data we've seen from the program? And what should we be expecting there?

No, that's a great question. So let me start by saying I'm very excited about the ASGCT data with the caveat that I can't speak about it in great detail because it's embargoed. So the date, I think, is in our press release, but it's on a Friday, let's say that's next Friday, which is 19, between 12 to 2 is when the information will be presented in front of the post.

So if someone is there, hopefully, you all will go review it. What is stated about gene therapy, and I've been in drug development for a very long time, but it's very rare, unusual where I see preclinical data translate directly into the clinic in the human. I saw this with the SMA program and I was CMO, Chief Medical Officer of Axis. I did comment that we are seeing this with GAN now where the preclinical data appears to translate into the human based on the 14 patients we've dosed. And what I would state is that the Rett preclinical data that's being presented at ASGCT next week is very interesting, but the detail as you decipher them, I think will hopefully show that we have a very good construct with the Amira technology that hopefully is validated in this preclinical data set that will be presented next week.

And to go beyond that, I'm also hoping that once we start dosing patients, both adults and hopefully children, all this preclinical work that has been done in these different roared models and other models will now translate almost 1 to 1 in the human and hopefully create an SMA-like situation and Zolgensma. So again, to tie this back together, I'm sincerely hoping that the preclinical data presented next week at Rett, which I think I hope will find impactful will translate into the human and give us hope that we have something clinically meaningful in this gene therapy product.

(Operator Instructions) The next question comes from Joon Lee with Truist Securities.

This is Mahdi on for June. So given the ultra-rare situation for GAN, is it at all feasible to do a double-blind placebo-controlled trial or not? And also for objective measures like Emporis, is there the aim for getting a statistically significant change for this for this measure? And is that, again, given the ultra-rare situation, is that possible or not?

Excellent question. When we think about ultra-rare diseases like this, first, we come into the question of what's the practicality of doing an RCT in a blinded fashion with the placebo control. I think with this disease, that's not possible. We simply don't have enough patients to power a study to find statistical significance. And that's why we're using our data to look at patients' own control as well as natural history to serve as a control, right? With this disease, when we have a natural history as a control, it serves as a powerful comparator arm. Now that we have several other patients within the natural history to compare to the intervention, we can determine the treatment effect and find statistical significance.

mFARS, as you mentioned, is objective. It's, of course, the neurologic exam which I love. So that adds some objectivity to it. And we're able to detect changes, especially when we use the disease progression model to show differences. The next step is to find clinical meaningfulness in that data. And that's our hope with the biology, the histology, the electrophysiology to the clinical impact, right? It's quite widespread over the central and peripheral nervous system, and we're able to detect those changes. Suku?

Yes. Simon. And one more thing I have to emphasize is the NIH has generated the largest natural histodatabase that exists in the world for GAN. That's point one. Number 2 is the interventional data that we have is also the largest for a disease like GAN. The third thing that Denihan we've discovered in the natural history study is that all these patients have ataxia and therefore, makes them fast an appropriate clinical measure to see the efficacy of the product. right?

Yes, the neuroanatomy fits perfectly what we're seeing in patients and 100% have ataxia. So why not measure that? And why not use biologic measures to show that correlation between biology to function?

This is Sean. Maybe just to add one other point. is that the FDA asked for a double-blind placebo-controlled trial in the context of MFM being the primary endpoint because they thought it was effort-based. And when we ask them for clarification around that, they did come back and acknowledge that in this type of a disease state with an ultra-orphan population, you could not feasibly conduct that study. But they also then went on to say and reinforce published guidance that a well-controlled trial that has clinically meaningful endpoints that are objective would be considered.

And hopefully, what you're getting a flavor for here and that Dr. Bhai is providing additional color on is that as we've interrogated the database, and as Suku said, it's the largest database in the world for GAN, we're seeing across multiple clinical domains that affect both the CNS and the PNS what we think is a clinically meaningful impact on objective endpoints that are unequivocally objective. And so that's why we're so confident or I should say, encouraged by the data that we're generating this far. And we look forward to showing it in much more detail at the upcoming R&D Day.

Can I add a point to that, too, with the natural history data, what's crucial for this model, which we've shown is that it's homogeneous, it's predictable. And based off those reasons, we can now use that model to compare to our intervention patients.

Awesome. So if I may, I reformulate the question and ask it a different way. If mFARS was the primary objective from the beginning, would that trial data so far make it convincing for FDA to approve?

Awesome question, right? In hindsight, when we take a look at this data, right, it's clear. When we look at the neuroanatomy, it's quite clear. But with an ultra-rare disease like this, it's always a struggle, right? What's the initial hypothesis and what are we getting? So if we were to go back and make that the primary, of course, right, this is a disease that has ataxia on 100% of patients, and those are the findings that we're seeing that we believe to be clinically meaningful.

And I would add one more thing to what Dr. Bhai just said is that these patients who were treated were 6 years and older. So the disease had already progressed somewhat given it was neurodegenerative. And given that we saw 6 or more patients having restoration of snap or center innovation potential and other measures of electrophysiology that could potentially translate into a clinically meaningful effect that could be far greater if not treated much earlier given that the neodegeneration may have not progressed as much. Obviously, to caveat it by saying we haven't studied cellenthan 6 years away, and we have great interest to see if we can have that kind of significant impact in younger patients as well. So collectively, we are very encouraged with the data that we are seeing and looking forward to meeting with the FDA and talk with them.

(Operator Instructions) The next question comes from Gil Blum with Needham & Co.

Maybe a good place to start is just to help me understand the order of events. So you're having your R&D event ahead of an FDA meeting in the third quarter. Why not the other way around?

So that's a good question. So keep in mind, though, that we are putting the meeting request in the second quarter, and there is going to be a certain time lag before we actually get the meeting, hopefully. But at the same time, we are generating significant amounts of data from prespecified endpoints post our analysis and the model that Dr. Bhai was talking about that we think are truly clinically relevant, and there is significant interest from many who would like to understand not only the impact of our intrathecal gene therapy on this specific ultra-rare disease to understand benefit over risk but there's also significant interest in trying to understand the clinical platform, what kind of impact would it have across a broad aspect of neurodegenerative and neurodevelopmental disorders.

And I would again remind you that if you look at the SMA program with Georgens, the IV formulation had a significant impact in SMA Type 1 and some other subtypes as well. But recently in Novartis released more data with the intrathecal approach where they have a significant clinical impact in SMA Type 2, Type 3, and Type 4 as well. So this platform, I think, being proven over time will give us hopefully a simple route of administration, which is through lumber puncture that could address many complex disorders of the central nervous system.

So due to the significant interest, we think it's appropriate to have this R&D meeting towards the end of June so that we can talk about some of our findings that I think will be hopefully significantly relevant to the patients in question.

I think the other thing to add to that is that in a perfect world, there would be a scientific conference that lines up with us, and that would have been the preferable way to disclose things. But in all candor, we stepped through this analysis, not knowing exactly what the outcomes are going to be. And at this point, we're very encouraged by what we're seeing. And you hopefully can tell from the way we're coming across on the call that we feel this is very compelling. And so we felt that was the best way to disclose it, explain how we were going to move things forward with the agency and highlight our rationale and then provide the data that, in our view, justifies our conviction with the program.

Okay. That's fair. And bear with me here for a second because this is a little complicated. So Sarepta is on top of minds of everyone. And I'll venture to say that the reason the FDA was okay with Sarepta submitting on an external control for a functional measure is just because they have a random study right behind it. And that's basically the key difficulty, right? And if you're doing an open-label study for a functional endpoint, the training aspect of it, right, that's what the FDA does not like. And that gets me to my actual question. Is mFARS more objective?

As a neurologist, of course. I would say that it is. So for example, if you hold your arms out in front of you if you happen to have a headset on and you take your right pointer finger and touch your nose, there's a little bit of jitter there. Not to most people, that might not be much. But to me, I can pick that up. Now if you have even more jitter, I can pick that up further and start to objectify what your exam findings look like. And so that's mFARS. So not only are there objective pieces from the neurologic exam there that I can point towards and say, this has intra and interrater reliability, but there's also objective measures that then back that up. So if I was a bad neurologist and not diagnosing correctly, I have objective measures there to help support that. But mFARS as far as I would argue, has objective measures within that.

Okay. Because in my opinion, I think I might go to the heart of the matter because it's really obvious that the FDA doesn't like external controls when it comes to things that can be trained in an open-label study.

And also like the Reata product that was approved with mFARS.

Exactly. But there is a history on the regulatory side that sometimes it's just impractical to ask for randomized fiscal control trials and perfection when it comes to clinical trial design. But when there is no therapeutic option available and these kind of studies, especially in ultra-disease show clinical benefit, I think that it becomes a negotiation between the regulatory agencies and the sponsor in making sure the product is appropriately made available to the patient community in question.

And I would go even further to state that Peter Marks and colleagues have been out there, obviously, encouraging a serious discussion between the agency SBIR and the sponsor of this kind of ultrarare disease program in having some flexibility if the benefit for is the risk, and there's no other therapeutic option available to the patient community, such as in GAN, which is an ultra-rare disease, if you meet these patients and see and see what happens to them, I think that pathway is now open for us to appropriately position our data, talk to the FDA and show them that we ourselves are convinced. And hopefully, we can convince them that it's an appropriate product for approval such that patients can use the gene therapy product.

And I think one other thing to add that we would simply be that in addition to mFARS, what we're trying to do is also demonstrate multiple endpoints that are objective. And I don't want to talk about Snap or EIM, CMA, and MRIs, right? So could just show that no matter where you're kind of cutting the bread, you're getting an effect in all these domains that can only be attributable to the drug. And I think with the model that we've got put together, we have a very scientifically driven, data-driven control that we can point to, and this highlights the effectiveness across all these different domains. So put very simply, we're not hanging our hat on any one thing. It is the totality of the data.

(Operator Instructions) This concludes the question-and-answer session. I would like to turn the conference back over to Mr. Sean Nolan for any closing remarks. Please go ahead.

Thank you, operator, and thanks to all of you for joining us on the call this afternoon. Have a great rest of your day. Take care.

This concludes today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.